ClinicalTrials.gg
Active, not recruitingNCT04302454ADOPTUpdated Apr 4, 2025

Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

A Phase 3 interventional study of Radiotherapy and Leuprorelin in Prostate Cancer, sponsored by University Medical Center Groningen. Active, not recruiting at 13 sites in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University Medical Center Groningen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Planned enrollment
11th of 69
280 · median 77
Started
2020
with 2 others
Phase 3
26 of 70
3 open now
Primary completion
2027-10
later than 10 of 15 live
Registered
53rd of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 11th largest by planned enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2020, is one of 26 in phase 3, reaches primary completion later than 10 of the 15 other live ones, and was the 53rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • Oligometastasis
  • Stereotactic Body Radiation Therapy
  • Androgen Deprivation Therapy
  • Biochemical recurrence
  • PSMA PET/CT
  • Metastases-directed radiotherapy
  • Metastases progression-free survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven initial diagnosis of adenocarcinoma of the Prostate.
  2. Biochemical recurrence of prostate cancer following primary local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed salvage radiotherapy) according to the EAU guidelines 2018. BCR after surgery: PSA > 0.1ng/ml. BCR after radiotherapy: PSA nadir +2 ng/ml or 3 consequent rises in PSA level (after exclusion of possible bounce effect).
  3. Minimal 1 lesion and maximum 4 lesions (bone + lymph nodes) in total, without evidence of visceral .

    1. Nodal relapse (N1) in the pelvis on PSMA-PET/CT with a maximum of 4 positive lymph nodes. The upper limit of the pelvis is defined as the aortic bifurcation.
    2. Nodal relapse (M1a) on PSMA-PET/CT above the aortic bifurcation with a maximum of 3 positive lymph nodes.
    3. Bone relapse on PSMA-PET/CT with a maximum of 3 lesions.
    4. Combination of a, b, c with a maximum of 4 metastases.
  4. Age > 18 years.
  5. Recent PSMA-PET/CT scan within 60 days prior to randomization.
  6. PSA \< 10 ng/ml.
  7. In case of chronic use of finasteride the PSA value should be \< 5 ng/ml.
  8. WHO performance state 0-2.
  9. Signed prior to registration/randomization.

Exclusion criteria

Exclusion criteria

  1. Visceral .
  2. PSA ≥ 10 ng/ml.
  3. PSA-doubling time ≤ 3 months.
  4. ADT or chemotherapy for recurrent PCa.
  5. Testosterone \< 1.7 nmol/l
  6. Painful metastases needed pain medication (> level 1 pain medication) .
  7. Invasive active cancers other than superficial non-melanoma skin cancers.
  8. Inability or unwillingness to understand the information on trial-related topics, to give or to fill out QoL questionnaires.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Radiotherapy without hormonal therapy

    Metastase-directed radiotherapy without the addition of hormonal therapy

    Radiation: Radiotherapy

  • Experimental
    Radiotherapy combined with hormonal therapy

    Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)

    Radiation: Radiotherapy · Drug: Leuprorelin

Interventions

  • RadiationRadiotherapy

    Radiotherapy

    Also known as: MDRT, Metastase-directed radiotherapy, SBRT, Stereotactic body radiotherapy

  • DrugLeuprolideStudies of LeuprolideLeuprolide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hormonal therapy

    Also known as: Eligard

06

What researchers measure

Primary outcomes

  1. Metastases progression-free survival (MPFS)

    The primary aim of this project is to test the hypothesis that the addition of ADT to MDRT in well-selected PCa patients with oligo-metastatic disease (OM) prolongs the metastases progression-free survival (MPFS) compared to MDRT alone

    Time frame: 2.5 years after treatment

07

Study locations

13 sites
08

References and documents

Publications

  • Janssen J, Staal FHE, Brouwer CL, Langendijk JA, de Jong IJ, van Moorselaar RJA, Schuit E, Verzijlbergen JF, Smeenk RJ, Aluwini S. Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial. BMC Cancer. 2022 May 2;22(1):482. doi: 10.1186/s12885-022-09523-2. PubMed 35501744 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Oct 2027, 91 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 91 months is close to that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Mar 10, 2020
StartActual
Mar 19, 2020
Primary completionEst.
Oct 21, 2027
CompletionEst.
Dec 1, 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04302454
Collaborators
Dutch Cancer Society
Responsible party
Sponsor
First posted
Mar 10, 2020
Start date
Mar 19, 2020
Primary completion
Oct 21, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

S. Al-Uwini, PhD
principal investigator · UMCG

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion